Amgen Seeks ‘Return to Growth’ for Tepezza as More Convenient Formulation Aces Phase 3

Phase 3positiveTepezzaNegative

AI Analysis

Summary

Amgen's more convenient formulation of Tepezza achieved Phase 3 success, though current sales declined 1% to $457 million in Q4 2025, prompting efforts to return the thyroid eye disease drug to growth.

Clinical Trial Data

Phase

Phase 3

Primary Endpoint

Met

Financial Highlights

Revenue

$457 million

Outcome Details

More convenient formulation aced Phase 3

Importance:6/10

Sentiment:

-0.30

Phase 3 successsales declineformulation developmentthyroid eye disease

Related Companies

$AMGN

Read the original article

Published by BioSpace on April 7, 2026 10:58 AM

Read Original